Skip to main content


Table 1 Emerging targets with clinical significance in urothelial carcinoma

From: Emerging therapeutic agents for genitourinary cancers

Molecular target Class Trial Disease setting Agent Experimental treatment Study phase Estimated completion
PD-1/PD-L1 CPI NCT02807636 (IMvigor130) Untreated mUC Atezolizumab Atezolizumab + (Carboplatin) (Gemcitabine) (Cisplatin) Phase III November 2020
NCT02853305 (Keynote-361) Untreated mUC Pembrolizumab Pembrolizumab + (Cisplatin) (Carboplatin) (Gemcitabine) Phase III May 2020
CTLA-4 NCT02516241 (DANUBE) Untreated mUC Tremelimumab Durvalumab + tremelimumab or durvalumab monotherapy Phase III September 2019
CD122 Cytokine Modulation NCT02983045 (PIVOT-2) Advanced tumors (mUC) NKTR-214 NKTR-214 + nivolumab or NKTR-214 + nivolumab + ipilimumab Phase I/II June 2021
NCT03785925 (Pivot-10) Cisplatin-ineligible, mUC patients with low PD-L1 expression NKTR-214 NKTR-214 + nivolumab Phase III May 2022
NCT03138889 (PROPEL) Advanced tumors (mUC) NKTR-214 NKTR-214 + pembrolizumab or NKTR-214 + atezolizumab Phase I May 2020
IL-7 NCT03513952 Advanced, inoperable or mUC CYT107 CYT107 + atezolizumab Phase I December 2020
TGFβ + PD-1 NCT02517398 Advanced tumors (mUC) MSB0011359C (M7824) MSB0011359C (M7824) Phase I August 2020
CD137/4-1BB NCT02845323 Cisplatin-ineligible MIBC Urelumab Urelumab + nivolumab or nivolumab monotherapy Phase II January 2020
OX40 NCT02554812 (JAVELIN Medley) Advanced tumors (mUC) PF-04518600 Avelumab Utomilumab PF-04518600 PD 0360324 Phase II December 2020
NCT03217747 Advanced tumors (UC) PF-04518600 Avelumab UtomilumabPF-04518600 Radiation Cisplatin Phase I/II August 2023
IDO T Cell Metabolism NCT03361865 (Keynote-672) (ECHO307) Cisplatin-ineligible UC Epacadostat Epacadostat + pembrolizumab Phase III September 2020
NCT03374488 (Keynote-698) Cisplatin-ineligible mUC Epacadostat Epacadostat + pembrolizumab Phase III August 2020
VEGF TKI NCT03133390 Cisplatin-ineligible mUC Bevacizumab Bevacizumab + atezolizumab Phase II January 2020
NCT03272217 Cisplatin-ineligible untreated mUC Bevacizumab Bevacizumab + atezolizumab Phase II April 2021
cMET/VEGF NCT02717156 Untreated mUC EphB4-HSA EphB4-HAS + pembrolizumab Phase II November 2020
NCT03534804 (PemCab) Cisplatin-ineligible mUC Cabozantinib Cabozantinib + pembrolizumab Phase II September 2023
NCT03170960 Advanced tumors (UC) Cabozantinib Cabozantinib + atezolizumab Phase I/II December 2020
FGFR NCT02546661 (BISCAY) Previously-treated MIBC AZD4547 MEDI4736 Olaparib AZD1775 Vistusertib AZD9150 Selumetinib Phase Ib March 2020
NCT03123055 (FIERCE-22) mUC Vofatamab Vofatamab + pembrolizumab Phase I/II September 2022
NCT03473756 (FORT-2) FGFR-positive mUC Rogaratinib Rogaratinib + atezolizumab Phase Ib/II July 2022
Nectin-4 ADC NCT03288545 (EV-103) mUC Enfortumab Vedotin Enfortumab vedotin + pembrolizumab Phase I September 2024
NCT03219333 (EV-201) mUC previously-treated with CPI Enfortumab Vedotin Enfortumab vedotin Phase II May 2025
NCT02091999 Nectin-4-positive mUC Enfortumab Vedotin Enfortumab vedotin Phase I December 2020
NCT03474107 (EV-301) Previously-treated mUC Enfortumab Vedotin Enfortumab vedotin Phase III September 2021
HER-2 NCT03523572 mUC Trastuzumab Deruxtecan (DS-8201a) Trastuzumab Deruxtecan (DS-8201a) Phase I/II September 2020
  1. All trial information obtained through publicly accessible